- Home
- FRSX vs VYNE Comparison
FRSX vs VYNE Comparison
Compare FRSX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRSX
- VYNE
- Stock Information
- Founded
- FRSX N/A
- VYNE 2003
- Country
- FRSX Israel
- VYNE United States
- Employees
- FRSX N/A
- VYNE N/A
- Industry
- FRSX Computer Software: Prepackaged Software
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- FRSX Technology
- VYNE Health Care
- Exchange
- FRSX Nasdaq
- VYNE Nasdaq
- Market Cap
- FRSX 8.2M
- VYNE 7.9M
- IPO Year
- FRSX 2017
- VYNE 2018
- Fundamental
- Price
- FRSX $2.09
- VYNE $0.31
- Analyst Decision
- FRSX
- VYNE Buy
- Analyst Count
- FRSX 0
- VYNE 2
- Target Price
- FRSX N/A
- VYNE $8.00
- AVG Volume (30 Days)
- FRSX 75.7K
- VYNE 1.7M
- Earning Date
- FRSX 09-21-2025
- VYNE 11-06-2025
- Dividend Yield
- FRSX N/A
- VYNE N/A
- EPS Growth
- FRSX N/A
- VYNE N/A
- EPS
- FRSX N/A
- VYNE N/A
- Revenue
- FRSX $452,000.00
- VYNE $476,000.00
- Revenue This Year
- FRSX N/A
- VYNE N/A
- Revenue Next Year
- FRSX N/A
- VYNE N/A
- P/E Ratio
- FRSX N/A
- VYNE N/A
- Revenue Growth
- FRSX N/A
- VYNE N/A
- 52 Week Low
- FRSX $1.98
- VYNE $0.28
- 52 Week High
- FRSX $18.41
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- FRSX 32.79
- VYNE 32.36
- Support Level
- FRSX $2.30
- VYNE $0.28
- Resistance Level
- FRSX $2.63
- VYNE $0.33
- Average True Range (ATR)
- FRSX 0.21
- VYNE 0.02
- MACD
- FRSX 0.01
- VYNE 0.03
- Stochastic Oscillator
- FRSX 15.44
- VYNE 43.45
About FRSX Foresight Autonomous Holdings Ltd.
Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.